Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Influenza.

M D Khare1, M Sharland

  • 1Paediatric Infectious Diseases Unit, St. George's Hospital, Blackshaw Road, London, SW17 0QT, UK.

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Newer antiviral drugs, neuraminidase inhibitors like zanamivir and oseltamivir, show promise for preventing and treating influenza A and B. While effective with minimal side effects, further research is needed for routine clinical use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings.

The Journal of antimicrobial chemotherapy·2023
Same author

Auditing use of antibiotics in Zimbabwean neonates.

Infection prevention in practice·2021
Same author

Multi-drug-resistant infections in the COVID-19 era: a framework for considering the potential impact.

The Journal of hospital infection·2020
Same author

Correction to: Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review.

Antimicrobial resistance and infection control·2020
Same author

Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review.

Antimicrobial resistance and infection control·2020
Same author

Interventions to prevent urinary catheter-associated infections in children and neonates: a systematic review.

Journal of pediatric urology·2018
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Current influenza A antivirals (amantadine, rimantadine) lack efficacy against influenza B.
  • Neuraminidase inhibitors offer broader activity against both influenza A and B viruses.

Purpose of the Study:

  • To review the efficacy and safety of neuraminidase inhibitors for influenza.
  • To identify areas for further research before widespread clinical adoption.

Main Methods:

  • Literature review of studies on zanamivir and oseltamivir.
  • Analysis of efficacy data for prophylaxis and treatment.
  • Assessment of reported adverse effects and drug limitations.

Main Results:

  • Neuraminidase inhibitors demonstrated 67-82% efficacy in influenza prophylaxis.

Related Experiment Videos

  • Treatment with these drugs reduced illness duration by 1-1.5 days.
  • Adverse effects were minimal, with no apparent central nervous system impact.

    • Conclusions:

    • Zanamivir and oseltamivir are effective influenza antivirals with favorable safety profiles.
    • Limitations include zanamivir's bioavailability and potential use in asthmatics.
    • Further comparative studies and cost-effectiveness analyses are necessary.